Edition:
India

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

69.50EUR
18 May 2018
Change (% chg)

€-1.00 (-1.42%)
Prev Close
€70.50
Open
€70.30
Day's High
€70.70
Day's Low
€69.50
Volume
72,720
Avg. Vol
132,005
52-wk High
€79.80
52-wk Low
€59.00

Chart for

About

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Overall

Beta: 0.36
Market Cap(Mil.): €8,348.02
Shares Outstanding(Mil.): 118.36
Dividend: 0.33
Yield (%): 0.47

Financials

BRIEF-Biomerieux Q1 Sales Up 3.4 Percent 587 Million Euros

* NET DEBT AMOUNTED TO EUR 84 MILLION AT MARCH 31, 2018, VERSUS EUR 156 MILLION AT DECEMBER 31, 2017

19 Apr 2018

BRIEF-Biomerieux Acquires Astute Medical Inc. For About $90 Mln In Cash

* ANNOUNCED ON WEDNESDAY, ACQUISITION OF ASTUTE MEDICAL INC FOR ABOUT $90 MLN IN CASH

05 Apr 2018

French and Benelux stocks-Factors to watch on April 5

April 5 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

05 Apr 2018

BRIEF-Biomerieux FY Sales Up At 2.29 Billion Euros

* FY OPERATING INCOME EUR 315 MILLION VERSUS EUR 282 MILLION YEAR AGO

28 Feb 2018

BRIEF-Biomerieux FY ‍Sales Rise 10.2 Pct To EUR 2,288 Million

* ‍SALES MOMENTUM IN 2017 WITH 10.2% GROWTH IN SALES TO EUR 2,288 MILLION IN SALES​

23 Jan 2018

BRIEF-Biomerieux Appoints Alexandre Merieux As CEO And Chairman

* ALEXANDRE MÉRIEUX APPOINTED CHAIRMAN AND CEO OF BIOMÉRIEUX Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Dec 2017

Earnings vs. Estimates